Batroxobin Maranhao

Total Page：16

File Type：pdf, Size：1020Kb

PENTAPHARM Batroxobin maranhao Description: Batroxobin is a thrombin-like proteolytic enzyme isolated from the venom of Bothrops atrox. It splits the 16 Arg-17 Gly bond in the A-chain of fibrinogen and causes the release of fibrinopeptide A and the formation of fibrin I monomer or Des-AA-monomer which spontaneously aggregates into a clot of fibrin I. Batroxobin also induces the release of tPA from endothelium. Application: Due to its specific action on fibrinogen and its ability to clot platelet-rich plasma without affecting the integrity and functions of the platelets, and thanks to its insensitivity to thrombin inhibitors, batroxobin has found several applications as a tool in blood coagulation research and diagnosis. Batroxobin can be used to determine fibrinogen in plasma, to measure the batroxobin clotting time (Reptilase time) as a heparin-insensitive parallel to the thrombin time, to investigate dysfibrinogenemia, and to test the contractile system of platelets. Origin: Bothrops atrox snake venom MW: approx. 43’000 Storage: May be used by the expiry date given on the label when stored unopened, protected from moisture. Avoid contamination of the reagents by micro-organisms. Shipment of product does not require cooling during the time of transportation. Vial 1’000 BU/vial 2° – 8°C References: Stocker K. Application of snake venom proteins in the diagnosis of hemostatic disorders. In: Medical Use of Snake Venom Proteins, Stocker K, ed. Boca Raton: CRC-Press 1990; 213-52. Package size: Vial containing 1’000 BU Code: 101-06 FOR RESEARCH USE ONLY. NOT FOR HUMAN USE OR DRUG USE. Registered as DSM Nutritional Products Ltd Branch Pentapharm Dornacherstrasse 112, CH-4147 Aesch BL/Switzerland Phone: +41 61 706 48 48, Fax: +41 61 706 48 00, www.pentapharm.com .

Copy Link

Recommended publications

MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
[Show full text]
(12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
[Show full text]
Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
[Show full text]
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
[Show full text]
Correlation of the Production of Plasminogen Activator with Tumor Metastasis in Bi 6 Mouse Melanoma Cell Lines
[CANCER RESEARCH 40, 288-292, February 1980 0008-5472/80/0040-0000$02.00 Correlation of the Production of Plasminogen Activator with Tumor Metastasis in Bi 6 Mouse Melanoma Cell Lines Bosco Shang Wang,2 Gerard A. McLoughlin,3 Jerome P. Richie, and John A. Mannick Deportment of Surgery, Peter Bent Brigham Hospital (B. S. W., G. A. M., J. P. R., J. A. M.j, and Department of Pathology (B. S. W.j, Harvard Medical School, Boston, Massachusetts 02115 ABSTRACT circulating cancer cells were easily detected in patients whose blood had a higher level of FA. The correlation between the production of plasminogen ac Although the FA of a tumor has been suggested as correlat tivator (PA) of tumors and their metastatic potential was stud ing with its metastatic potential, direct and quantitative evi ied. Bi 6 melanoma cells and â€˜â€˜Bi6 mets' â€˜cells (harvested from dence to support this hypothesis is lacking. Therefore, we have the pulmonary metastatic nodules of C57BL/6J mice bearing investigated this issue by comparing the FA of the Bi 6 mouse Bi 6 isografts) were examined with respect to their fibrinolytic melanoma and several of its sublines varying in their potential activity (FA) in tissue culture. Bi 6 mets cells had a significantly for forming metastases. higher FA than did Bi 6 cells. Fl (a Bi 6 subline with a lower incidence of metastasis) and Fl 0 (a highly metastatic Bi 6 subline) were also studied. Fl 0 cells produced more FA than MATERIALS AND METHODS did Fi cells. The difference between the FA's of these tumors Tumors.
[Show full text]
Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Edward R. Kastenhuber1, Javier A. Jaimes2, Jared L. Johnson1, Marisa Mercadante1, Frauke Muecksch3, Yiska Weisblum3, Yaron Bram4, Robert E. Schwartz4,5, Gary R. Whittaker2 and Lewis C. Cantley1,* Affiliations 1. Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 2. Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA. 3. Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA. *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Coagulopathy is recognized as a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. Other host proteases, including TMPRSS2, are recognized to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing viral entry.
[Show full text]
Thrombin-Jmi
THROMBIN-JMI - thrombin, topical (bovine) THROMBIN-JMI; THROMBIN-JMI PUMP SPRAY KIT; THROMBIN-JMI SYRINGE SPRAY KIT - thrombin, topical (bovine) THROMBIN-JMI SYRINGE SPRAY KIT - thrombin, topical (bovine) THROMBIN-JMI EPISTAXIS KIT - thrombin, topical (bovine) King Pharmaceuticals, Inc. ---------- THROMBIN, TOPICAL U.S.P. (BOVINE ORIGIN) THROMBIN-JMI® Thrombin, Topical (Bovine) must not be injected! Apply on the surface of bleeding tissue. DESCRIPTION The thrombin in Thrombin, Topical (Bovine Origin) THROMBIN-JMI® is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin of bovine origin in the presence of calcium chloride. It is supplied as a sterile powder that has been freeze-dried in the final container. Also contained in the preparation are mannitol and sodium chloride. Mannitol is included to make the dried product friable and more readily soluble. The material contains no preservative. THROMBIN-JMI® has been chromatographically purified and further processed by ultrafiltration. Analytical studies demonstrate the current manufacturing process’ capability to remove significant amounts of extraneous proteins, and result in a reduction of Factor Va light chain content to levels below the limit of detection of semi-quantitative Western Blot assay (<92 ng/mL, when reconstituted as directed). The clinical significance of these findings is unknown. CLINICAL PHARMACOLOGY THROMBIN-JMI® requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which thrombin clots blood is dependent upon the concentration of both thrombin and fibrinogen.
[Show full text]
Effect of Intravenous Thrombolysis with Alteplase on Clinical Efficacy
Brazilian Journal of Medical and Biological Research (2021) 54(5): e10000, http://dx.doi.org/10.1590/1414-431X202010000 ISSN 1414-431X Research Article 1/8 Effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction Jinhua Wang1 00 00, Xia Fang2 00 , Dongliang Wang1 00 , and Yuan Xiao1 00 1Department of Neurology, The People’s Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China 2Department of Gynecology, The People’s Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China Abstract This study aimed to explore the effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction. A total of 120 patients with acute cerebral infarction were divided into two groups by the random number table method, with 60 patients in each group: observation group (intravenous thrombolysis with alteplase) and control group (intravenous thrombolysis with batroxobin). The clinical efficacy after a 14-day treatment was observed. Serum C-reactive protein (CRP), tumor necrosis factor a (TNF-a), interleukin-6 (IL-6), CD62p, GMP- 140, and neuron-specific enolase (NSE) were measured. Scores of National Institutes of Health Stroke Scale (NIHSS), Mini- Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) were determined. The total effective rate in the observation group was 81.67%, which was higher than the 61.67% in the control group (Po0.05).
[Show full text]
Distinctive Role of Histidine-16 of the B,8 Chain of Fibrinogen in the End-To
Proc. Nati. Acad. Sci. USA Vol. 83, pp. 591-593, February 1986 Biochemistry Distinctive role of histidine-16 of the B,8 chain of fibrinogen in the end-to-end association of fibrin (polymerization/chemical modification/affinity chromatography) AKIRA SHIMIZU, YUJI SAITO, AND YUJI INADA Laboratory of Biological Chemistry, Tokyo Institute of Technology, Ookayama, Meguro-ku, Tokyo 152, Japan Communicated by John D. Ferry, September 12, 1985 ABSTRACT Photooxidation of fibrinogen reduced the includes 17th to 19th amino acid residues in Aa chain of batroxobin-induced fibrin polymerization. The fibrin fragment fibrinogen, specifically inhibits fibrin association and has des-AB N-DSK, which contains the binding sites termed A and proved itselfuseful for the elucidation ofassociation sites (7). B, lost the ability to bind to the site termed a in fibrinogen- These examples stress the critical role played by arginine-19 Sepharose upon the oxidation of histidine-16 in the BP chain of of Aa chain and some residues adjacent to it in the NH2- fibrinogen [Shimizu, A., Saito, Y., Matsushima, A. & Inada, terminal domain. On the other hand, very short fragments Y. (1983) J. Biol. Chem. 258, 7915-7917]. Some of the derived from the y chain of the COOH-terminal domain fragments, which became unable to bind to fibrinogen-Seph- (threonine-374 to valine-411 or threonine-374 to glutamic arose due to the destruction of site A, however, retained the acid-396) quite efficiently inhibited the association and sug- ability to bind to D-dimer-Sepharose, which contains both sites gested the importance ofthat region for the association (8, 9).
[Show full text]
Protein C Product Monograph 1995 COAMATIC® Protein C Protein C
Protein C Product Monograph 1995 COAMATIC® Protein C Protein C Protein C, Product Monograph 1995 Frank Axelsson, Product Information Manager Copyright © 1995 Chromogenix AB. Version 1.1 Taljegårdsgatan 3, S-431 53 Mölndal, Sweden. Tel: +46 31 706 20 00, Fax: +46 31 86 46 26, E-mail: [email protected], Internet: www.chromogenix.se COAMATIC® Protein C Protein C Contents Page Preface 2 Introduction 4 Determination of protein C activity with 4 snake venom and S-2366 Biochemistry 6 Protein C biochemistry 6 Clinical Aspects 10 Protein C deficiency 10 Assay Methods 13 Protein C assays 13 Laboratory aspects 16 Products 17 Diagnostic kits from Chromogenix 17 General assay procedure 18 COAMATIC® Protein C 19 References 20 Glossary 23 3 Protein C, version 1.1 Preface The blood coagulation system is carefully controlled in vivo by several anticoagulant mechanisms, which ensure that clot propagation does not lead to occlusion of the vasculature. The protein C pathway is one of these anticoagulant systems. During the last few years it has been found that inherited defects of the protein C system are underlying risk factors in a majority of cases with familial thrombophilia. The factor V gene mutation recently identified in conjunction with APC resistance is such a defect which, in combination with protein C deficiency, increases the thrombosis risk considerably. The Chromogenix Monographs [Protein C and APC-resistance] give a didactic and illustrated picture of the protein C environment by presenting a general view of medical as well as technical matters. They serve as an excellent introduction and survey to everyone who wishes to learn quickly about this field of medicine.
[Show full text]
Exogenous Procoagulant Factors As Therapeutic and Biotechnological
isord D ers od & lo T r B f a n o s l f a u n s r Journal of i o u n o Chudzinski-Tavassi et al., J Blood Disorders Transf 2014, 5:5 J ISSN: 2155-9864 Blood Disorders & Transfusion DOI: 10.4172/2155-9864.1000209 Review Article OpenOpen Access Access Exogenous Procoagulant Factors as Therapeutic and Biotechnological Tools Ana Marisa Chudzinski-Tavassi*, Linda Christian Carrijo Carvalho, Miryam Paola Alvarez-Flores and Sonia Aparecida de Andrade Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, Brazil Abstract A diversity of animal venoms and secretions has been described to affect the hemostatic system with actions on blood coagulation and fibrinolytic pathways. These biological materials are rich sources of proteins and peptides with distinct biochemical properties, which have a biological function for the animal. Snake venoms are one of the richest sources of exogenous hemostatic factors, especially procoagulant proteins. Insects are another important source of proteins and peptides targeting the hemostatic system. Exogenous procoagulant factors have a large functional diversity and present potential applications in health and biotechnology. They have been important tools for the diagnosis and therapy of several blood coagulation disorders. Recently, many studies have pointed out that exogenous hemostatic factors can also display non-hemostatic functions, bringing new perspectives for the study of these molecules. Keywords: Exogenous hemostatic factors; Coagulation; Fibrinolysis; venom production, storage and
[Show full text]
Mechanism of Batroxobin Binding to Fibrinogen and Fibrin 1
JBC Papers in Press. Published on April 23, 2013 as Manuscript M113.464750 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.M113.464750 Mechanism of batroxobin binding to fibrinogen and fibrin BATROXOBIN BINDS FIBRIN WITH HIGHER AFFINITY AND PROMOTES CLOT EXPANSION TO A GREATER EXTENT THAN THROMBIN Trang T. Vu1,2, Alan R. Stafford1,3, Beverly A. Leslie1,3, Paul Y. Kim1,3, James C. Fredenburgh1,3 and Jeffrey I. Weitz1,2,3,4† Thrombosis and Atherosclerosis Research Institute1 and the Departments of Medical Sciences,2 Medicine,3 and Biochemistry and Biomedical Sciences,4 McMaster University, Hamilton, Ontario, Canada. Running title: Mechanism of batroxobin binding to fibrinogen and fibrin To whom correspondence should be addressed: Dr. Jeffrey Weitz, Thrombosis and Atherosclerosis Research Institute, 237 Barton St. E., Hamilton, Ontario L8L 2X2, Canada Phone: 905-574-8550 Fax: (905) 575-2646 E-mail: [email protected] Downloaded from Keywords: Batroxobin, thrombin, fibrin(ogen), fibrinopeptides Background: Snake venom protease γA/γ'-fibrin(ogen) than γA/γA-fibrin(ogen). batroxobin clots fibrinogen in a manner In contrast, batroxobin binds both http://www.jbc.org/ distinct from thrombin. fibrin(ogen) isoforms with similar high Results: Batroxobin binds fibrin(ogen) with affinity (Kd values of about 0.5 μM) even higher affinity than thrombin and promotes though it does not interact with the γ'-chain. greater clot expansion. The batroxobin binding sites on Conclusion: Batroxobin’s distinctive fibrin(ogen) only partially overlap with by guest on July 22, 2019 interaction with fibrin(ogen) may contribute to those of thrombin because thrombin its unique pattern of fibrinopeptide release.
[Show full text]